Abstract:We read great interest in the risk factors of critical or mortal COVID-19 cases, recently reported by Ye et al. in this journal.1Zheng Z. Peng F. Xu B. Zhao J. Liu H. Peng J. et al.Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis.J Infect. 2020; 81: e16-e25Abstract Full Text Full Text PDF PubMed Scopus (1507) Google Scholar Here we paid more attention about the long-term lung sequelae among survivors of severe COVID-19. With more than 21 million people worldwide recovered from COVID-19, early analysis suggested a high rate of patients had residual abnormal lung function and fibrotic remodeling on CT, especially in survivors of severe SARS-CoV-2 associated pneumonia.2Mo X. Jian W. Su Z. Chen M. Peng H. Peng P. et al.Abnormal pulmonary function in COVID-19 patients at time of hospital discharge.Eur Respir J. 2020; 552001217Crossref PubMed Scopus (517) Google Scholar,3Brian P.P. Kai E.S. Husham S. Harmeet B. Gerald J.B. H Henry G. Radiology-pathology correlation in recovered COVID-19, demonstrating organizing pneumonia.Am J Respir Crit Care Med. 2020; 202: 598-599Crossref Scopus (44) Google Scholar These might contribute to long-term impairment of lung function or even lung transplants. The early identification of patients at higher risk of lung injury and fibrotic damage is critical.4George P.M. Wells A.U. Jenkins R.G. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy.Lancet Respir Med. 2020; 8: 807-815Abstract Full Text Full Text PDF PubMed Scopus (733) Google Scholar Therefore, we performed an observational cohort study that compared fibrosis and non-fibrosis group to investigate the potential indicators for post-fibrosis. The two-center retrospective study was approved by the institutional review board of Xianning Central Hospital and Huangshi Central Hospital, both in Hubei Province. The informed consent was waived. From December 19, 2019 to March 5, 2020, a total of 430 consecutive patients with positive RT-PCR were reviewed. Finally 81 survivors who recovered from severe COVID-19 pneumonia were enrolled. The median hospitalization was 26 days; all had at least three follow-up CT scans after discharge, and the median period between the discharge and the latest CT scan was 58 days (IQR: 25–46). Pulmonary fibrosis was diagnosed based on the extensive and persistent fibrotic changes, including parenchymal bands, irregular interfaces, reticular opacities, and traction bronchiectasis with or without honeycombing on the follow-up CT scans. CT scores were evaluated by two experienced cardiothoracic radiologists independently, and quantified by the percentage of high attenuation area using thresholds with pixels between 0 and −700 HU via Chest Imaging Platform (http://chestimagingplatform.org/). Fibrosis grouping was reached by consensus. Comparative analysis were performed with R software, covering age, sex, prior medical history, signs and symptoms, laboratory data, oxygen supply, ICU admission, and treatments. The statistical difference was assessed with the unpaired, 2-tailed chi-square test for categorical variables and t-test or Mann-Whitney for continuous variables. P<0.05 indicated a statistically significant difference. All patients were divided into two groups: fibrosis (N = 42) and non-fibrosis (N = 39). Fibrosis cases were older (p < 0.001), disproportionately male (p = 0.036), with more underlying diseases (Any [78% vs. 41%]; diabetes [31% vs. 23%]; hypertension [40% vs. 23%]; chronic pulmonary disease [21% vs. 7%]; chronic liver disease [19% vs. 13%]; cardiovascular and cerebrovascular diseases [29% vs. 15%]) than non-fibrosis cases. It is worth stressing that fibrosis group had much higher rate of fever (p = 0.034), long prehospital duration of fever (p = 0.001), and shortness of breath (p = 0.024) on admission. Abnormal parameters including leucocytosis, neutrophilia, lymphopenia, eosinopenia, elevated CRP and d-dimer, had significant difference between groups (Fig. 1A). Details were provided in Supplementary Table. Importantly, the longitudinal analysis demonstrated distinct features (Fig. 1B). In fibrosis group, we noticed that the levels of neutrophils, NLR, CRP and LDH were markedly above the normal range within 4 weeks, while CRP dramatically elevated unlike other parameters declining in the next 4 weeks. Conversely, in non-fibrosis group, CRP and LDH elevated within 2 weeks, then sharply dropped back to normal. Lymphopenia and eosinopenia occurred in most patients on admission. Note that the sustained low values of lymphocytes and the continuous absence of eosinophil early in-hospital showed a statistically significant difference. Fibrosis group suffered from more severe complications, resulting in higher rates of ICU admission and more intensive treatments to control the disease progression (Fig. 1C). To date, available data indicate that more than a third of recovered patients develop fibrotic abnormalities on discharge.2Mo X. Jian W. Su Z. Chen M. Peng H. Peng P. et al.Abnormal pulmonary function in COVID-19 patients at time of hospital discharge.Eur Respir J. 2020; 552001217Crossref PubMed Scopus (517) Google Scholar, 5George P.M. Barratt S.L. Condliffe R. Desai S.R. Devaraj A. Forrest I. et al.Respiratory follow-up of patients with COVID-19 pneumonia.Thorax. 2020; (thoraxjnl-2020-215314)Crossref Scopus (229) Google Scholar Additionally, 47% of patients had impaired DLCO and 25% had reduced TLC.2Mo X. Jian W. Su Z. Chen M. Peng H. Peng P. et al.Abnormal pulmonary function in COVID-19 patients at time of hospital discharge.Eur Respir J. 2020; 552001217Crossref PubMed Scopus (517) Google Scholar It seems even worse in severe survivors. In our study, all survivors had varying degrees of fibrotic damage, ranging from subtle linear opacities to diffuse distribution of crazy-paving pattern (Fig. 1D); 52% (42/81) of patients showed extensive and unimproved fibrosis in a longitudinal analysis of CT findings. The radiographical abnormalities strongly correlated with long-term impairment of lung function.6Burnham E.L. Hyzy R.C. Paine R. Coley C. Kelly A.M. Quint L.E. Chest CT features are associated with poorer quality of life in acute lung injury survivors.Cri Care Med. 2013; 41: 445-456Crossref PubMed Scopus (54) Google Scholar It remains unclear why certain individuals are able to recover from lung injury, whereas others develop into fibrotic damage.7Margot C. Arthur P. Laurent S. Marc H. Xavier M. Rapid onset honeycombing fibrosis in spontaneously breathing patient with Covid-19.Eur Respir J. 2020; 2001808PubMed Google Scholar Several markers associated with mortality risk, including age, illness severity, length of ICU stay, mechanical ventilation and hyper-inflammatory markers, might be the potential predictors for pulmonary fibrosis.8Vasarmidi E. Tsitoura E. Spandidos D.A. Tzanakis N. Antoniou K.M Pulmonary fibrosis in the aftermath of the COVID-19 era (Review).Exp Ther Med. 2020; 20: 2557-2560PubMed Google Scholar The highlight here reported a series of early indicators after tracing backwards to the features of disease progression between fibrosis and non-fibrosis group. Other than common factors of advancing age, male and underlying diseases, that had been well described,9Gentile F. Aimo A. Forfori F. Catapano G. Clemente A. Cademartiri F. COVID-19 and risk of pulmonary fibrosis: the importance of planning ahead.Eur J Prev Cardiol. 2020; 27: 1442-1446Crossref PubMed Scopus (56) Google Scholar it should be noted that the dynamic evolution of inflammatory markers within two weeks of hospitalization might point to fibrosis. More importantly, the long prehospital duration of fever, the rapid and shallow breathing, and the absence of eosinophil on admission might be a combination of early indicators. All these can be readily obtained in clinical practice; thus, it holds great promise for large-scale use in a catastrophic pandemic. Certain limitations and potential biases may exist in our study. Firstly, due to the relatively short-term of clinical follow-up, a large cohort of prospective and long-term analysis should be performed for more evidence. Secondly, only survivors of severe or critical COVID-19 with a high likelihood of lung injury were enrolled in our study, when all resources were stretched in a pandemic. The patients with mild or moderate infection would be added for analysis in our further study. This two-center study was approved by the ethics committee, with a waiver of informed consent. Great thanks for the Xianning Central Hospital and Huangshi Central Hospital, both in Hubei Province. Thanks for all the valuable cases presented by these hospitals. We are grateful to all members of the frontline for their contribution to the SARS-CoV-2 outbreak. Download .docx (.03 MB) Help with docx files

COVID-19: Immunohistochemical Analysis of TGF-β Signaling Pathways in Pulmonary Fibrosis

TGF-β and CCL18 as Indicators for Predicting and Monitoring the Development of Pulmonary Fibrosis in Patients with COVID-19

TGF-{beta}1 Overexpression in Severe COVID-19 Survivors: Implications for Early-Phase Fibrotic Abnormalities and Long-Term Functional Impairment

TGF-β1 overexpression in severe COVID-19 survivors and its implications for early-phase fibrotic abnormalities and long-term functional impairment

SARS-CoV-2 Infection Triggers Profibrotic Macrophage Responses and Lung Fibrosis

The Role of Cytokines and Molecular Pathways in Lung Fibrosis following SARS-CoV-2 Infection: A Physiopathologic (Re)view

IL-4/IL-13 remodeling pathway of COVID-19 lung injury

Bulk RNA-Sequencing of small airway cell cultures from IPF and post-COVID lung fibrosis patients illustrates disease signatures and differential responses to TGF-β1 treatment

Lung Fibrosis after COVID-19: Treatment Prospects

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy

Mechanisms and Therapeutic Strategies for Pulmonary Fibrosis Post-COVID-19 ARDS: Insights from Comprehensive Bioinformatics

COVID‐19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts

The Potential Indicators for Pulmonary Fibrosis in Survivors of Severe COVID-19

Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies

The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors

Pulmonary Fibrosis in Critical Ill Patients Recovered from COVID-19 Pneumonia: Preliminary Experience

Pulmonary fibrosis secondary to COVID-19: a narrative review

Neutrophil Activity and Extracellular Matrix Degradation: Drivers of Lung Tissue Destruction in Fatal COVID-19 Cases and Implications for Long COVID

Prediction of the Development of Pulmonary Fibrosis Using Serial Thin-Section CT and Clinical Features in Patients Discharged after Treatment for COVID-19 Pneumonia

COVID-19-mediated pulmonary fibrosis:from mechanisms to medicines

Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID‐19